Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | TTK | P33981 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16513670 | 1.00 | CDK2 (0.45) | CDK2TTKCCNA2ZAP70IKBKB | |
| SCHEMBL16515298 | 0.91 | CDK2 (0.49) | CDK2TTKCCNA2IKBKBCDK4 | |
| SCHEMBL29847518 | 0.91 | CDK2 (0.49) | CDK2TTKCCNA2IKBKBCDK4 | |
| SCHEMBL16515089 | 0.91 | BRAF (0.44) | CDK2TTKCCNA2ZAP70EGFR | |
| SCHEMBL29847932 | 0.91 | BRAF (0.44) | CDK2TTKCCNA2ZAP70EGFR | |
| SCHEMBL16823283 | 0.90 | CDK2 (0.41) | CDK2TTKCCNA2ZAP70IKBKB | |
| SCHEMBL16515086 | 0.90 | MYLK4 (0.46) | CDK2TTKCCNA2ZAP70IKBKB | |
| SCHEMBL31679055 | 0.90 | MYLK4 (0.46) | CDK2TTKCCNA2ZAP70IKBKB | |
| SCHEMBL16823103 | 0.89 | ZAP70 (0.42) | CDK2TTKCCNA2ZAP70CDK4 | |
| SCHEMBL16514778 | 0.88 | CDK1 (0.50) | CDK2TTKCCNA2ZAP70EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | claimed |
| CN-109851617-B | Chemical entities, compositions, and methods | 润新生物公司 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CDK2 35/4885TTK 18/4885CCNA2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.